Sus Clinicals, Inc.’s Post

🇳🇴 Norway's precision medicine revolution is taking the fight to cancer! Discover how biotech companies like Nykode Therapeutics are teaming up with global pharma to develop innovative cancer vaccines and therapies. The IMPRESS-Norway clinical trial is paving the way for improved public cancer care through precision medicine. Want to know more about Norway's thriving ecosystem and its impact on cancer treatment? Click to learn more👇 #PrecisionMedicine #CancerResearch #BiotechInnovation #NorwegianHealthcare #InvestInNorway

We're thrilled to share that Vanessa B. Wookey, MD, an Assistant Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has received a grant from the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) to explore optimizing biomarker-directed therapy in metastatic colorectal cancer. Read more on Wookey’s research program, “Improving Biomarker Testing in Patients With Metastatic Colorectal Cancer Through Patient Education”: https://bit.ly/3qv34L0

🔬 F-Star and Takeda: Forging Next-Gen Cancer Therapies 🌟 Discover the powerful collaboration between F-Star and Takeda that's paving the way for cutting-edge cancer treatments! Dive into the innovation, research, and vision that are driving the future of oncology. 💪 Explore the partnership's impact in our latest article: https://hubs.la/Q022GvKk0

NEW from #ASCO2024 | The ABCs of ADCs: what does the future hold? 🎥 🇺🇸 Erika Hamilton, MD, Sarah Cannon Research Institute, delves into the future of #antibodydrugconjugates (#ADCs) in #oncology, encompasses insights from various #disease types, including #myeloma, #lungcancer, and #breastcancer 🩸 🫁 🌟 Dr Hamilton highlights the evolution of #ADCs over the past two decades, emphasizing their expansion beyond highly expressing targets to include #antigens with lower expression levels 🌟 She discusses the promising development of ADCs targeting novel antigens, such as TROP-2, and explores innovative strategies like payload masking and #bispecific targeting to overcome resistance and enhance tolerability 🌟 Dr Hamilton envisions #ADCs revolutionizing #oncologycare and underscores the importance of understanding #antigenexpression and optimizing drug #sequencing in future #research and #clinicalpractice 🔦 Learn more 👉 https://lnkd.in/e2ZN-b8r #VJOncology #Oncologynews American Society of Clinical Oncology (ASCO)

A comprehensive review of PARPi+ARPI combos in 1st line mCRPC - Neeraj Agarwal, MD, FASCO Rana McKay Alicia Morgans OncoAlert UroToday + GU OncToday Prostate Cancer Foundation #Cancer #OncoDaily #Oncology #ProstateCancer

Building on its successful strategy in MM, Johnson & Johnson is tackling solid tumors with a similar approach of combining therapeutic mechanisms. The pharma to present trio of studies on bispecific Rybrevant in lung cancer at #ESMO23

🇺🇸🔬 #ASCO2024 | A few takeaways from the American Society of Clinical Oncology (ASCO) Annual Meeting on lung cancer, breast cancer, hepatocellular carcinoma, and melanoma. This confirms high unmet needs where XENOTHERA’s XON7 could bring strong benefits.   👉 For more information on XON7, please refer to our latest press release « XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France » :  https://lnkd.in/eFxHhU6V   #CancerResearch #Treatment #Oncology #Biotech #Immunotherapy

The Cancer Research Institute and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the IPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers. “There is a large body of clinical evidence for LOQTORZI, including positive phase 3 studies published in top-tier scientific journals, showing efficacy and safety in multiple tumor types,” says Jay Campbell, Managing Director, Clinical Accelerator and Venture Fund at CRI. “This level of scientific evidence is what we are looking for when selecting immunotherapies to bring into our network, with the goal of advancing clinically meaningful solutions to patients. We are grateful to have the opportunity to collaborate with Coherus BioSciences and ENB Therapeutics on this study and excited to be working with them on this novel combination that we hope will lead to improved outcomes in these patient populations.” More: https://bit.ly/3QzMzH8 #OvarianCancer #CancerResearch

 A comprehensive review of PARPi+ARPI combos in 1st line mCRPC

We’re proud to have wonderful partners, like Alex Spira, MD, PhD, FACP, to continue to evaluate the potential of our investigational cMET-targeting ADC for patients with non-small cell lung cancer.    Together, we are re-envisioning cancer therapy.   Visit our website, below, or contact our team at [email protected] for more information on our trial: https://lnkd.in/ejAiVB_s   #KisMET01 #ADC #CancerResearch #Biotechnology #Oncology #NSCLC #LungCancer #ClinicalTrial #LCAM #LungCancerAwareness #LungCancerAwarenessMonth